Clinical Trial Update: Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers [Phase 2]

View source ↗

Summary

A completed Phase 2 safety study evaluated bevacizumab (Avastin) with pelvic radiation in women with recurrent gynecologic cancers; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of the Vulva
• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer
• Vaginal Cancer

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Cervical Cancer, Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-07-02